---
title: "Aptose Presents 86% CRc and 86% MRD-negativity in TUSCANY AML Triplet Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289779990.md"
description: "Aptose Biosciences reported strong results from its TUSCANY Phase 1/2 trial of the tuspetinib triplet (TUS+VEN+AZA) for newly diagnosed AML. The study showed an 86.2% composite complete response rate and 86.4% MRD-negativity in evaluable patients. The regimen was well-tolerated with no treatment-related deaths or significant safety signals, demonstrating high frontline activity across various dosing cohorts."
datetime: "2026-06-15T12:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289779990.md)
  - [en](https://longbridge.com/en/news/289779990.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289779990.md)
---

# Aptose Presents 86% CRc and 86% MRD-negativity in TUSCANY AML Triplet Trial

**Aptose reported an 86.2% composite complete response rate and 86.4% MRD-negativity among CR/CRh patients in its TUSCANY Phase 1/2 tuspetinib triplet trial.**

**Key Highlights:**

-   32 newly diagnosed AML patients dosed with TUS+VEN+AZA across 40, 80, 120 and 160 mg tuspetinib cohorts.
-   Overall CRc in 29 response-evaluable patients was 86.2%, showing high frontline activity for the triplet.
-   MRD-negativity in CR/CRh patients was 86.4%; MRD-negative rate among all dosed patients was 62.5%.
-   160 mg cohort (n=13) achieved 76.9% CRc; all 4 TP53-mut/complex karyotype patients had composite complete remissions.
-   Triplet was well tolerated: no treatment-related deaths, no QTc prolongation, CPK elevations or differentiation syndrome; TUS PK unaffected by VEN, AZA, antifungals or food.

Original SEC Filing: Aptose Biosciences Inc. \[ APTOF \] - 8-K - Jun. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APTOF.US](https://longbridge.com/en/quote/APTOF.US.md)
- [APTO.US](https://longbridge.com/en/quote/APTO.US.md)

## Related News & Research

- [Analyst Reaffirms Buy on Adaptive Biotechnologies, Lifting Price Target to $25 Amid Strong MRD Momentum and Raised 2026 Guidance](https://longbridge.com/en/news/294342713.md)
- [TEM: Q2 2026 delivered 22% revenue growth, net income turnaround, and major MRD expansion via acquisition](https://longbridge.com/en/news/294408929.md)
- [Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates](https://longbridge.com/en/news/294255863.md)
- [Moleculin reports interim results from MIRACLE trial in r/r AML patients](https://longbridge.com/en/news/294705884.md)
- [RARE: Record Q2 revenue and upcoming gene therapy launches position the company for 2027 profitability](https://longbridge.com/en/news/294883644.md)